HUP0104693A2 - Eljárás az ízületi gyulladás MEK inhibitorokkal való kezelésére - Google Patents

Eljárás az ízületi gyulladás MEK inhibitorokkal való kezelésére

Info

Publication number
HUP0104693A2
HUP0104693A2 HU0104693A HUP0104693A HUP0104693A2 HU P0104693 A2 HUP0104693 A2 HU P0104693A2 HU 0104693 A HU0104693 A HU 0104693A HU P0104693 A HUP0104693 A HU P0104693A HU P0104693 A2 HUP0104693 A2 HU P0104693A2
Authority
HU
Hungary
Prior art keywords
group
atom
general formula
alkyl
formula
Prior art date
Application number
HU0104693A
Other languages
English (en)
Inventor
David Thomas Dudley
Craig Mason Flory
Alan Robert Saltiel
Original Assignee
Warner-Lambert Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Co. filed Critical Warner-Lambert Co.
Publication of HUP0104693A2 publication Critical patent/HUP0104693A2/hu
Publication of HUP0104693A3 publication Critical patent/HUP0104693A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)

Abstract

Eljárás emlősökön az ízületi gyulladás kezelésére vagy megelőzésére,azzal jellemezve, hogy egy ízületi gyulladásban szenvedő és ilyenkezelésre szoruló betegnek, vagy pedig egy olyan betegnek, akirőlfeltételezhető, hogy ízületi gyulladás alakul ki nála, egy MEK-inhibitornak (a sejtosztódást kiváltó behatások által aktivált proteinkináz enzimet gátló anyagnak), például valamely (I) vagy (II)általános képletű vegyületnek, gyógyászatilag elfogadható sójának,észterének, amidjának vagy prodrug változatának az ízületigyulladás-ellenes hatás kifejtéséhez szükséges mennyiségét adagolják, ahol az(I) általános képletben R1 jelentése hidrogénatom, hidroxilcsoport, 1-8 szénatomos alkilcsoport, 1-8 szénatomos alkoxicsoport, halogénatom,trifluor-metil-csoport vagy cianocsoport; R2 jelentése hidrogénatom;R3, R4 és R5 jelentése egymástól függetlenül hidrogénatom,hidroxilcsoport, halogénatom, trifluor-metil-csoport, 1-8 szénatomosalkilcsoport, 1-8 szénatomos alkoxicsoport, nitrocsoport, cianocsoportés/vagy -(O vagy NH)m-(CH2)n-R9 általános képletű csoport, ahol R9jelentése hidrogénatom, hidroxilcsoport, karboxilcsoport vagy NR10R11általános képletű csoport; n jelentése 0, 1, 2, 3 vagy 4; m jelentése0 vagy 1; és R10 és R11 jelentése egyenként, egymástól függetlenülhidrogénatom vagy 1-8 szénatomos alkilcsoport, vagy pedig együttesjelentésük, azzal a nitrogénatommal együtt, amelyhez kapcsolódnak, egy3-10 tagú gyűrűből leszármaztatható csoport lehet, amely adott esetben1, 2 vagy 3 további heteroatomot, például oxigénatomot, kénatomot, NHképletű csoportot és/vagy N-(1-8 szénatomos alkilcsoport) általánosképletű csoportot tartalmazhat, és Z jelentése COOR7 általános képletűcsoport, tetrazolilcsoport, CONR6R7, CONHNR10R11 vagy CH2OR7 általánosképletű csoport, ahol R6 és R7 jelentése egymástól függetlenülhidrogénatom, 1-8 szénatomos alkilcsoport, 2-8 szénatomosalkenilcsoport, 2-8 szénatomos alkinilcsoport, (1-8 szénatomos alkil)-karbonil-csoport, arilcsoport, heteroarilcsoport, 3-10 szénatomos,adott esetben 1, 2 vagy 3 heteroatomot, például oxigénatomot,kénatomot, NH képletű csoportot és/vagy N-(alkilcsoport) általánosképletű csoportot tartalmazó cikloalkilcsoport; vagy pedig R6 és R7jelentése együtt, továbbá azzal a nitrogénatommal együtt, amelyhezkapcsolódnak, egy 3-10 tagú gyűrűből leszármaztatható csoport, amelyadott esetben 1, 2 vagy 3 további heteroatomot, például oxigénatomot,kénatomot, NH képletű csoportot és/vagy N-(alkilcsoport) általánosképletű csoportot tartalmazhat; és a (II) általános képletben R1a,R2a,R3a, R4a, R5a, R6a, R7a, R9a, R10a és R11a jelentése rendre azonosaz (I) általános képletre megadott, megfelelő R1, R2, R3, R4, R5, R6,R7, R9, R10 és R11 jelentésével; továbbá ahol bármely fentialkilcsoport, alkenilcsoport, arilcsoport, heterociklusos csoport ésalkinilcsoport helyettesítetlen vagy hal
HU0104693A 1998-12-16 1999-12-15 Treatment of arthritis with mek inhibitors HUP0104693A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11254498P 1998-12-16 1998-12-16
US16465199P 1999-11-10 1999-11-10
PCT/US1999/029783 WO2000035436A2 (en) 1998-12-16 1999-12-15 Treatment of arthritis with mek inhibitors

Publications (2)

Publication Number Publication Date
HUP0104693A2 true HUP0104693A2 (hu) 2002-03-28
HUP0104693A3 HUP0104693A3 (en) 2003-12-29

Family

ID=26810075

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0104693A HUP0104693A3 (en) 1998-12-16 1999-12-15 Treatment of arthritis with mek inhibitors

Country Status (8)

Country Link
EP (1) EP1143957A3 (hu)
JP (1) JP2002532415A (hu)
KR (1) KR100609800B1 (hu)
AU (1) AU776788C (hu)
CA (1) CA2346448A1 (hu)
HU (1) HUP0104693A3 (hu)
IL (1) IL143236A0 (hu)
WO (1) WO2000035436A2 (hu)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL147617A0 (en) * 1999-07-16 2002-08-14 Warner Lambert Co Method for treating chronic pain using mek inhibitors
US7030119B1 (en) 1999-07-16 2006-04-18 Warner-Lambert Company Method for treating chronic pain using MEK inhibitors
KR20020012315A (ko) * 1999-07-16 2002-02-15 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법
ES2461854T3 (es) 2000-07-19 2014-05-21 Warner-Lambert Company Llc Ésteres oxigenados de ácidos 4-yodofenilamino-benzhidroxámicos
NZ518726A (en) 2001-05-09 2004-06-25 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
KR20020096367A (ko) * 2001-06-19 2002-12-31 주식회사 티지 바이오텍 관절염 예방 또는 치료제 및 그것의 스크리닝 방법
KR20020096368A (ko) * 2001-06-19 2002-12-31 주식회사 티지 바이오텍 연골세포의 분화촉진, 연골세포의 탈분화 억제 또는탈분화된 연골세포의 재분화 촉진제, 그것의 스크리닝방법 및 그것을 이용한 연골세포의 제조방법
MXPA06000921A (es) 2003-07-24 2006-03-30 Warner Lambert Co Derivados de benzamidazoles como inhibidores de mek.
US8084645B2 (en) 2003-09-19 2011-12-27 Chugai Seiyaku Kabushiki Kaisha 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
BRPI0415710A (pt) 2003-10-21 2006-12-19 Warner Lambert Co formas polimórficas de n-[(r)-2,3-dihidróxi-propóxi]-3,4-diflúor-2-(2-flúor-4-io dofenilamino)-benzamida
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
CN101912400B (zh) 2004-06-11 2013-06-26 日本烟草产业株式会社 用于治疗癌症的5-氨基-2,4,7-三氧代-3,4,7,8-四氢-2H-吡啶并[2,3-d]嘧啶衍生物和相关化合物
TWI361066B (en) 2004-07-26 2012-04-01 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
EP1934174B1 (en) * 2005-10-07 2011-04-06 Exelixis, Inc. Azetidines as mek inhibitors for the treatment of proliferative diseases
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
AU2008337286B2 (en) 2007-12-19 2014-08-07 Cancer Research Technology Limited Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
JP5746630B2 (ja) 2008-11-10 2015-07-08 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換スルホンアミドフェノキシベンズアミド
AU2009328507A1 (en) 2008-12-19 2011-07-14 Medirista Biotechnologies Ab Oxidized cardiolipin as a novel pro-inflammatory factor
US8962606B2 (en) 2009-10-21 2015-02-24 Bayer Intellectual Property Gmbh Substituted benzosulphonamides
WO2011047795A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted benzosulphonamides
US20120263714A1 (en) 2009-10-21 2012-10-18 Bayer Intellectual Property Gmbh Substituted halophenoxybenzamide derivatives
EP2531502B1 (en) 2010-02-01 2014-04-02 Cancer Research Technology Limited 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
WO2012055953A1 (en) 2010-10-29 2012-05-03 Bayer Pharma Aktiengesellschaft Substituted phenoxypyridines
WO2013013188A1 (en) 2011-07-21 2013-01-24 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
CA2860676A1 (en) 2012-01-09 2013-07-18 Novartis Ag Organic compositions to treat beta-catenin-related diseases
BR112015008113B1 (pt) 2012-10-12 2022-05-24 Exelixis, Inc. Novo processo para preparar compostos para uso no tratamento de câncer
JP6243918B2 (ja) 2012-10-16 2017-12-06 トレロ ファーマシューティカルズ， インコーポレイテッド Ｐｋｍ２調節因子およびそれらの使用方法
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
TR201911151T4 (tr) 2013-03-14 2019-08-21 Tolero Pharmaceuticals Inc Jak2 ve alk2 inhibitörleri ve bunların kullanım yöntemleri.
NZ710929A (en) 2013-03-15 2018-02-23 Novartis Ag Antibody drug conjugates
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
CN106659790A (zh) 2014-08-12 2017-05-10 诺华股份有限公司 抗cdh6抗体药物缀合物
JP6681905B2 (ja) 2014-09-13 2020-04-15 ノバルティス アーゲー Ａｌｋ阻害剤の併用療法
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
KR20170084202A (ko) 2014-11-14 2017-07-19 노파르티스 아게 항체 약물 접합체
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
SI3237418T1 (sl) 2014-12-23 2019-06-28 Novartis Ag Spojine triazolopirimidina in njihove uporabe
MX2017012295A (es) 2015-03-25 2018-01-09 Novartis Ag Derivados formilados n-heterociclicos como inhibidores de fgfr4.
EP3310813A1 (en) 2015-06-17 2018-04-25 Novartis AG Antibody drug conjugates
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
MX2018016331A (es) 2016-06-20 2019-05-20 Novartis Ag Formas cristalinas de compuesto de triazolopirimidina.
CN109790166A (zh) 2016-06-20 2019-05-21 诺华股份有限公司 咪唑并吡啶化合物用于治疗癌症
EP3472161B1 (en) 2016-06-20 2020-03-25 Novartis AG Triazolopyridine compounds and uses thereof
GB201702144D0 (en) 2017-02-09 2017-03-29 Annexin Pharmaceuticals Ab Therapeutic compositions
WO2018163051A1 (en) 2017-03-06 2018-09-13 Novartis Ag Methods of treatment of cancer with reduced ubb expression
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
AU2018274216A1 (en) 2017-05-24 2019-12-12 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
EP3630162A1 (en) 2017-05-24 2020-04-08 Novartis AG Antibody-cytokine engrafted proteins and methods of use
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
CN111655288A (zh) 2017-11-16 2020-09-11 诺华股份有限公司 组合疗法
CN112533602A (zh) 2018-04-05 2021-03-19 大日本住友制药肿瘤公司 Axl激酶抑制剂及其用途
JOP20210001A1 (ar) 2018-07-10 2021-01-05 Novartis Ag مشتقات 3-(5- هيدروكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخدامها لمعالجة أمراض مرتبطة ببروتين ذات أصبع الزنك من عائلة (ikaros 2 (ikzf2
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
KR102643582B1 (ko) 2018-07-25 2024-03-05 어드밴스드 엑셀러레이터 어플리케이션즈 안정한 농축 방사성 핵종 복합체 용액
CA3103995A1 (en) 2018-07-26 2020-01-30 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
JP7328323B2 (ja) 2018-08-17 2023-08-16 ノバルティス アーゲー ＳＭＡＲＣＡ２／ＢＲＭ ＡＴＰａｓｅ阻害剤としての尿素化合物及び組成物
US20210346527A1 (en) 2018-09-25 2021-11-11 Advanced Accelerator Applications (Italy) Srl Combination Therapy
EP3873532A1 (en) 2018-10-31 2021-09-08 Novartis AG Dc-sign antibody drug conjugates
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
MX2021009371A (es) 2019-02-12 2021-09-10 Sumitomo Pharma Oncology Inc Formulaciones que comprenden inhibidores de proteina cinasa heterociclicos.
CN113490528A (zh) 2019-02-15 2021-10-08 诺华股份有限公司 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
EP3924055B1 (en) 2019-02-15 2024-04-03 Novartis AG Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
MX2021011289A (es) 2019-03-22 2021-11-03 Sumitomo Pharma Oncology Inc Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
CA3145864A1 (en) 2019-07-03 2021-01-07 Sumitomo Dainippon Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
JP2022550353A (ja) 2019-09-26 2022-12-01 ノバルティス アーゲー アザキノリン化合物およびその使用
MX2022007759A (es) 2019-12-20 2022-07-19 Novartis Ag Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
AU2021288224A1 (en) 2020-06-11 2023-01-05 Novartis Ag ZBTB32 inhibitors and uses thereof
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AR123185A1 (es) 2020-08-10 2022-11-09 Novartis Ag Compuestos y composiciones para inhibir ezh2
WO2022043556A1 (en) 2020-08-31 2022-03-03 Novartis Ag Stable radiopharmaceutical composition
WO2022043558A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
CN117794929A (zh) 2021-02-02 2024-03-29 法国施维雅药厂 选择性bcl-xl protac化合物及使用方法
WO2022195551A1 (en) 2021-03-18 2022-09-22 Novartis Ag Biomarkers for cancer and methods of use thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
PE20240327A1 (es) 2021-04-13 2024-02-22 Nuvalent Inc Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2023008978A1 (ko) * 2021-07-30 2023-02-02 아주대학교산학협력단 Sncg를 표적으로 하는 퇴행성 질환 치료 또는 진단용 조성물
KR20230018813A (ko) * 2021-07-30 2023-02-07 아주대학교산학협력단 Pd-184352를 유효성분으로 포함하는 sncg 과발현 질환의 예방 또는 치료용 약학적 조성물
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2023225320A1 (en) 2022-05-20 2023-11-23 Novartis Ag Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
AR129382A1 (es) 2022-05-20 2024-08-21 Novartis Ag Conjugados de anticuerpo-fármaco inhibidores de bcl-xl y met y sus métodos de uso
WO2024023666A1 (en) 2022-07-26 2024-02-01 Novartis Ag Crystalline forms of an akr1c3 dependent kars inhibitor
WO2024189481A1 (en) 2023-03-10 2024-09-19 Novartis Ag Panras inhibitor antibody-drug conjugates and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9412711D0 (en) * 1994-06-24 1994-08-17 Cortecs Ltd Medical use of bromelain
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
WO1998028292A1 (en) * 1996-12-23 1998-07-02 Smithkline Beecham Corporation Novel piperidine containing compounds
US6251943B1 (en) * 1997-02-28 2001-06-26 Warner-Lambert Company Method of treating or preventing septic shock by administering a MEK inhibitor
GB9713726D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
EP1075467B1 (en) * 1998-05-05 2005-03-30 F. Hoffmann-La Roche Ag Pyrazole derivatives as p-38 map kinase inhibitors
WO1999061440A1 (en) * 1998-05-26 1999-12-02 Smithkline Beecham Corporation Novel substituted imidazole compounds

Also Published As

Publication number Publication date
EP1143957A2 (en) 2001-10-17
KR100609800B1 (ko) 2006-08-09
EP1143957A3 (en) 2002-02-27
AU776788C (en) 2005-10-27
WO2000035436A3 (en) 2001-10-18
IL143236A0 (en) 2002-04-21
JP2002532415A (ja) 2002-10-02
CA2346448A1 (en) 2000-06-22
HUP0104693A3 (en) 2003-12-29
AU776788B2 (en) 2004-09-23
WO2000035436A2 (en) 2000-06-22
AU2185800A (en) 2000-07-03
KR20010093840A (ko) 2001-10-29

Similar Documents

Publication Publication Date Title
HUP0104693A2 (hu) Eljárás az ízületi gyulladás MEK inhibitorokkal való kezelésére
HUP0004559A1 (hu) Ciklinfüggő kinázok aminotiazol inhibitorai, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0301249A2 (hu) APO B termelődés gátló benzamid-vegyületek ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0202381A2 (hu) MEK-inhibitor hatású fenil-amino-benzoesav-származékok alkalmazása krónikus fájdalom kezelésére szolgáló gyógyszerkészítmények előállítására
HUP0401104A2 (hu) Dipeptidil-peptidáz inhibitorként cukorbetegség megelőzésére és kezelésére alkalmazható (béta-aminoacil)-tetrahidroimidazo[1,2-a]pirazinok és - tetrahidrotriazolo[4,3-a]pirazinok, valamint az ezeket tartalmazó gyógyszerkészítmények
HUP0202001A2 (hu) DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok
RU95108387A (ru) Дикетопиперазин, способ его получения, фармацевтическая композиция, применение дикетопиперазина
HUP0203532A2 (hu) HPPAR-alfa aktivátor szubsztituált oxazol- és tiazolszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
EA199800184A1 (ru) Соединение бензимидазола
HUP0300318A2 (hu) Pirazolobenzodiazepin-származékok, mint CDK2 inhibitorok és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0002495A1 (hu) VLA-4 Által közvetített leukocita adhéziót gátló dipeptidszármazékok és rokon vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
KR940021063A (ko) 퀴놀론카르복실산 유도체, 이의 제조방법 및 용도
HUP0001446A2 (hu) HIV reverz transzkriptáz inhibitor hatású 4,4-diszubsztituált-3,4-dihidro-2(1H)-kinazolinon-származékok, alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények
HUP0201088A2 (hu) Új alfa-aminosav-szulfonil-vegyületek, eljárás előállításukra és ilyen vegyületeket tartalmazó gyógyászati készítmények
GEP20033028B (en) Heterocyclic Compounds as Inhibitors of Rotamase Enzymes, Method for Their Production, Pharmaceutical Composition Containing Them and Use Thereof
HUP0203575A2 (hu) Th2 differenciálódás inhibitorokat tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0001269A2 (hu) 2-Oxo-1-azetidin-szulfonsav-származékok és ezeket tartalmazó kombinált gyógyszerkészítmények
RU97109847A (ru) Производные аминотетразола, полезные как ингибиторы синтазы оксида азота
KR970707107A (ko) 산화질소 합성효소 억제제로서 유용한 아미노테트라졸 유도체(aminotetrazole derivatives useful as nitric oxide synthase inhibtors)
DK0583485T3 (da) Ethanolaminderivater med sympathomimetiske og anti-pollakisuria-virkninger
HUP0002853A2 (hu) 6,7-Helyzetben aszimmetrikusan diszubsztituált kinoxalinkarbonsav-származékok, és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
HUP0104607A2 (hu) MEK inhibitor alkalmazása transzplantátumok kilökődésének megelőzésére
NI200600270A (es) Una composición farmacéutica antimicobacteriana que comprende un farmaco antituberculosis
HUP0101469A2 (hu) 5-[(2-Imidazolidinilidén)-amino]-benzimidazol-származékok, előállításuk és alkalmazásuk javított metabolikus stabilitású alfa-adrenoceptor agonistákként
HUP0303204A2 (hu) 1-Metilkarbapenem-származékok és ezeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees